Kaufman, J., Duffy, J., Xu, J., Huettner, C. S., Xue, S., Michelini, V. V., … Kelley, M. J. (2018). Association of NGS mutational pattern with immune checkpoint inhibitor clinical benefit in solid tumors. In Journal of Clinical Oncology (Vol. 36, pp. e24274–e24274). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.e24274

Kaufman, Jacob, Jill Duffy, Jia Xu, Claudia S. Huettner, Shang Xue, Vanessa Vincenzi Michelini, Stephen J. Harvey, et al. “Association of NGS mutational pattern with immune checkpoint inhibitor clinical benefit in solid tumors.” In Journal of Clinical Oncology, 36:e24274–e24274. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e24274.

Kaufman J, Duffy J, Xu J, Huettner CS, Xue S, Michelini VV, et al. Association of NGS mutational pattern with immune checkpoint inhibitor clinical benefit in solid tumors. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. e24274–e24274.

Kaufman, Jacob, et al. “Association of NGS mutational pattern with immune checkpoint inhibitor clinical benefit in solid tumors.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. e24274–e24274. Crossref, doi:10.1200/jco.2018.36.15_suppl.e24274.

Kaufman J, Duffy J, Xu J, Huettner CS, Xue S, Michelini VV, Harvey SJ, Guertin CM, Hintze BJ, Spector NL, Kelley MJ. Association of NGS mutational pattern with immune checkpoint inhibitor clinical benefit in solid tumors. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. e24274–e24274.